Exploration of the Intervention Mechanism and Efficacy of Paired-pulse rTMS Treatment for Methamphetamine Use Disorder Based on the Frontopolar-Cerebellum

To investigate the mechanism and efficacy of a novel repetitive transcranial magnetic stimulation (rTMS) intervention model with paired frontopolar cortex (FPC) -cerebellar pulses on episodic methamphetamine use in patients on methadone maintenance treatment and to develop a novel physiotherapeutic intervention to optimise the treatment and management of addicted patients.

开始日期2024-09-01

申办/合作机构

上海市精神卫生中心（上海市心理咨询培训中心）

NCT06457243 / RecruitingN/AIIT

Closed-loop Neuromodulation Based on Individualised EEG Biomarkers of Methamphetamine Use Disorder

Using specific EEG biomarkers in methamphetamine-dependent individuals, this study systematically probes closed-loop continuous Theta-burst Stimulation (cTBS) based on brain states, assessing dosage, neurologic and behavioral effects, while comparing its efficacy with traditional open-loop cTBS methods.

开始日期2024-08-01

申办/合作机构

上海市精神卫生中心（上海市心理咨询培训中心）

NCT06454474 / Not yet recruitingN/AIIT

Individualized Neuromodulation Intervention Techniques for the Core Clinical Features of Drug Addiction

Using specific EEG biomarkers in methamphetamine-dependent individuals, this study systematically probes the effect of closed-loop tACS based on brain states

开始日期2024-06-30

申办/合作机构

上海市精神卫生中心（上海市心理咨询培训中心）

100 项与安非他明依赖相关的临床结果

登录后查看更多信息

100 项与安非他明依赖相关的转化医学

登录后查看更多信息

0 项与安非他明依赖相关的专利（医药）

登录后查看更多信息

314

项与安非他明依赖相关的文献（医药）

2024-12-01·Pediatric Blood & Cancer

How we approach steroid‐induced affective disorder in pediatric oncology

Review

作者: Elliott, D. Andrew ; Harman, Jennifer L.

AbstractHigh‐dose corticosteroids are an essential component of treatment for pediatric cancers. Yet, these agents often cause psychiatric disturbances including sleep disruption, steroid‐induced psychosis, and steroid‐induced affective disorder (SIAD). SIAD, identified as a specific form of substance/medication‐induced mental disorder, can present with various psychiatric symptoms, including mania, depression, irritability, and inconsolability. SIAD's varied presentation can lead to underdiagnosis and complicates clinical care, research, and identification of best practices. Here we highlight three pediatric oncology cases involving SIAD and discuss recommendations for supporting patients with SIAD, while introducing a tiered intervention framework (modified from Kazak) that stratifies responses based on symptom severity.

2024-12-01·Neuropharmacology

Methamphetamine-induced impairment of memory and fleeting neuroinflammation: Profiling mRNA changes in mouse hippocampus following short-term and long-term exposure

Article

作者: Liu, Xiaorui ; Li, Ming ; Wu, Laiqiang ; Chen, Teng ; Wu, Min ; Zhang, Wen ; Zhu, Li ; Chen, Yanjiong ; Wang, Rui ; Liang, Min ; Dong, Nan ; Zhu, Jie ; Wang, Biao ; Guan, Fanglin ; Ni, Tong ; Su, Linlan ; Jiang, Qingchen ; Wang, Shuai

Methamphetamine (METH) has been implicated in inducing memory impairment, but the precise mechanisms underlying this effect remain unclear. Current research often limits itself to singular models or focuses on individual gene or protein functions, which hampers a comprehensive understanding of the underlying mechanisms. In this study, we established three METH mouse exposure models, extracted hippocampal nuclei, and utilized RNA sequencing to analyze changes in mRNA expression profiles. Our results indicate that METH significantly impairs the learning and memory capabilities of mice. Additionally, we observed that METH-induced inflammatory responses occur in the early phase and do not further exacerbate with repeated injections. However, RNA sequencing revealed the persistent enrichment of inflammatory pathway molecules, which correlated with worsened behaviors. This suggests that although METH-induced neuroinflammation plays a critical role in learning and memory impairment, the continued enrichment of inflammatory pathway molecules is associated with behavioral outcomes. These findings provide crucial evidence for the potential application of immune intervention in METH-related disorders.

2024-10-01·Journal of Dual Diagnosis

Substance Use Disorder Admission Rates Before and After the Lockdown in a Large Addiction Center in Saudi Arabia: A Retrospective Cohort Study

Article

作者: Ramadan, Majed ; Batwa, Yara F.

Objective: This study aimed to examine the potential changes in substance use disorder (SUD) admission rates before and after the lockdown in a major addiction center in Saudi Arabia. Method: This retrospective cohort study extracted data from Al-Amal Hospital Electronic Health Record in the city of Dammam, Eastern region of Saudi Arabia. A total of 2,426 cases included in the analysis for patients who received services from the SUD treatment programs from 1/1/2015 to 31/12/2021. Results: Before the pandemic, there was a consistent increase in the admission rates for patients with substance use disorder. The highest proportion of increase were among unemployed, young, newly admitted patients. During lockdown, there was nearly a 70% reduction in SUDs-related admission rate. The age group 18-25 was seven-times more likely to be admitted for SUD after the lockdown. Amphetamine-related admissions were two times more likely to be admitted after the lockdown (Odds ratio (OR) 2.04; confidence interval (CI) 95%[1.64, 2.54]). Conclusions: There was nearly 70% reduction in SUDs admission rates during the lockdown. After the lockdown, a significant proportional increase in amphetamine use disorder admissions was observed mostly among the patients age group 18-24 with a history of a previous admissions. Determining populations at risk for high health care utilization is crucial in building a comprehensive and effective prevention strategy. Therefore, the need to adopt coordinated strategies and innovative, comprehensive approaches to benefit individuals with SUD is imperative to face the increased rate of SUD related admissions.

项与安非他明依赖相关的新闻（医药）

2024-10-28

·PRNewswire

$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT

CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION BOULDER, Colo. , Oct. 28, 2024 /PRNewswire/ -- Tessara Therapeutics, Psylo, and the University of Sydney are pleased to announce their receipt of a $3 million Cooperative Research Centres Projects (CRC-P) grant. Matching funds committed by the partners increases the total project investment to $6.2 million. The collaboration will focus on the development of neuroplastogens for the treatment of substance use disorders, with an emphasis on methamphetamine addiction. Methamphetamine addiction is a serious public health issue with limited effective treatments, highlighting the urgent need for new therapeutic approaches. This collaboration will leverage Tessara's cutting-edge RealBrain® microtissue technology, Psylo's pioneering neuroplastogens, and the University of Sydney's neuroscience expertise to address this critical challenge. Neuroplastogens are a novel class of compounds that promote neuroplasticity—the brain's capacity to adapt, reorganize, and form new neural connections. Unlike traditional treatments that mainly address symptoms, neuroplastogens aim to directly restore brain function by stimulating the growth and remodeling of neural circuits. This innovative approach has the potential to yield faster, more effective treatments for addiction and other mental health conditions. "This grant provides an exciting opportunity to combine the expertise of Tessara, Psylo, and the University of Sydney in developing transformative solutions for an urgent medical need," said Dr. Christos Papadimitriou, CEO and Managing Director of Tessara Therapeutics. "Tessara's high-throughput, human cell-based microtissues model brain function more accurately, driving more efficient discovery of drugs to treat addiction." Joshua Ismin, CEO and co-founder of Psylo, added, "At Psylo, our mission is to address critical gaps in mental health care with next-generation neuroplastogens. This collaboration not only accelerates our drug development but also brings us closer to providing meaningful solutions for addiction-related disorders." The project aims to significantly reduce the time and cost associated with neuroplastogen discovery, creating faster and more precise pathways for treating substance use disorders. "This collaboration represents a major step forward in developing research models that better reflect human biology, enabling more precise testing of new therapies," said Dr. Nick Everett, Research Fellow at the Brain and Mind Centre and University of Sydney's School of Psychology, and expert in behavioral neuroscience. "We believe this project could redefine how addiction therapeutics are developed." Scheduled to run from January 2025 to December 2027, the initiative will not only deliver promising neuroplastogen candidates but also enhance capabilities in neuroplasticity research, improve access to high-efficiency preclinical models, and promote sustainable research practices in drug discovery. This project received grant funding from the Australian Government under the Cooperative Research Centres Projects Round 16. About Tessara Therapeutics Tessara Therapeutics is a biotechnology company focused on developing novel drug discovery technologies and therapeutic solutions for mental health disorders. Their innovative approaches aim to revolutionize the preclinical drug development process, improving outcomes and reducing timeframes for new treatments. About Psylo Psylo is a biotechnology company dedicated to developing next-generation neuroplastogens to treat central nervous system disorders. By utilizing AI-guided drug design and translational biomarkers, Psylo aims to transform the neurotherapeutic landscape and improve the lives of millions worldwide. About the University of Sydney The University of Sydney is Australia's first university and a global top-20 higher education teaching and research institution. With world-class programs in neuroscience, psychology, and mental health, the university works in close collaboration with industry to transform how mental health conditions are understood and treated. SOURCE Psylo WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED